Author

S. Heskamp

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:CITE-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1

Frequent Co-Authors

J. Molkenboer-Kuenen· 2 shared A. B. van Spriel· 1 shared A. Bartolo-Ibars· 1 shared B. Deplancke· 1 shared C. Frielink· 1 shared C. G. Figdor· 1 shared D. Benitez-Ribas· 1 shared D. F. Boreel· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Molkenboer-Kuenen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Towards Effective CAIX-targeted Radionuclide and Checkpoint Inhibition Combination Therapy for Advanced Clear Cell Renal Cell Carcinoma

S. C. Kleinendorst, E. Oosterwijk, J. Molkenboer-Kuenen, C. Frielink, G. Franssen, D. F. Boreel, G. Tamborino, M. Gloudemans, M. Hendrikx, D. Kroon, J. Hillen, J. Bussink, S. Muselaers, P. Mulders, M. W. Konijnenberg, , S. Heskamp

This study investigates the combination of targeted radionuclide therapy and immune checkpoint inhibitors for advanced clear cell renal cell carcinoma, showing enhanced therapeutic outcomes and immune microenvironment changes.

bioRxiv · Feb 16, 2024Cancer Biology

Imaging the pharmacokinetics and therapeutic availability of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models

G. G. W. Sandker, J. Middelburg, E. Wilbrink, J. Molkenboer-Kuenen, E. Aarntzen, T. van Hall, S. Heskamp

This study investigates the pharmacokinetics and therapeutic availability of CD3xTRP1 antibody in mouse tumor models using imaging and biodistribution analyses.

bioRxiv · Jun 6, 2023 · PreprintImmunology

Immunofilaments Provide a Nanoscale Platform for In Vivo T Cell Expansion and Cancer Immunotherapy

L. Weiss, J. Weiden, Y. Dölen, E. Grad, E. A. W. van Dinther, M. Schluck, L. J. Eggermont, G. van Mierlo, U. Gileadi, A. Bartolo-Ibars, R. Raave, M. A. J. Gorris, K. Verrijp, M. Valente, B. Deplancke, , R. Hammink

This paper introduces immunofilaments that expand T cells in vivo, showing efficacy against melanoma when combined with immune checkpoint blockade.

bioRxiv · Oct 14, 2022Immunology